Complete remission of refractory immune thrombocytopenia (ITP) with a short course of Romiplostim

European Journal of Haematology

Volumn 91, Issue 4, 2013, Pages 376-377

  Thachil, Jecko ^a   Salter, Ian ^a   George, James N ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DAPSONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; ROMIPLOSTIM;

AGED; BONE MARROW BIOPSY; CASE REPORT; EPISTAXIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LETTER; LOW DRUG DOSE; MALE; METHEMOGLOBINEMIA; PRIORITY JOURNAL; REFRACTORY IMMUNE THROMBOCYTOPENIA; REFRACTORY THROMBOCYTOPENIA; REMISSION; SHORT COURSE THERAPY; SKIN BRUISING; SPLENECTOMY; THROMBOCYTE COUNT; VISUAL IMPAIRMENT;

AGED; BLOOD PLATELETS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; EYE HEMORRHAGE; HUMANS; MALE; PLATELET COUNT; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE; THROMBOPOIETIN; TREATMENT OUTCOME;

EID: 84884815187     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12165     Document Type: Letter

References (6)

1. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
2. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403.
3. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641-8.
4. Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica 2008;93:98-103.
5. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion 2013. doi:10.1111/trf.12139 [Epub ahead of print].
6. Bao W, Bussel JB, Heck S, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010;116:4639-45.